Results of Long-Term Iron-Chelating Therapy

Acta Haematologica

Volumn 95, Issue 1, 1996, Pages 26-36

  Gabutti, Vilma ^a   Piga, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chelation; Complications; Iron overload; Survival

Indexed keywords

DEFEROXAMINE; FERRITIN; IRON;

ARTICLE; BONE INJURY; CLINICAL PROTOCOL; DIABETES MELLITUS; DRUG TOXICITY; ELECTROCARDIOGRAM; EYE TOXICITY; GROWTH RETARDATION; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HUMAN; HYPOTHYROIDISM; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; LIVER FIBROSIS; LUNG TOXICITY; NEPHROTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PERCEPTION DEAFNESS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THALASSEMIA;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; DEFEROXAMINE; FEMALE; FERRITINS; HEMOSIDEROSIS; HUMANS; IRON CHELATING AGENTS; MALE; THALASSEMIA;

EID: 0030048681     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203853     Document Type: Article

References (108)

1. Modell B: Total management of thalassemia. Arch Dis Child 1977;52:489-500.
2. Modell B. Bcrdoukas V: The Clinical Approach to Thalassaemia. London, Grune &Stratton. 1984.
3. Buja LM. Roberts WC: Iron in the heart: Etiology and clinical significance. Am J Med 1971; 51:209-221.
4. Cohen A: Management of iron overload in pediatric patients. Hcmatol Oncol Clin North Am 1987;1:521-544.
5. Unger A, Hershko C: Hepatocellular uptake of ferritin in the rat. Br J Haematol 1974;28:169— 179.
6. O’Connell MJ. Halliwell B. Moorhouse CP. Aruoma Ol. Baum H. Peters TJ: Formation of hydroxyl radicals in the presence of ferritin and haemosiderin. Biochem J 1985:229:135-139.
7. Hershko C. Graham G. Bates GW. Rachmilc-witz EA: Non-specific serum iron in thalassemia: An abnormal scrum iron fraction of potential toxicity. Br J Haematol 1978:40:255-263.
8. Ahmed NK, Hanna M, Wang W: Nontransfer-rin-bound serum iron in thalassemia and sickle cell patients. Int J Biochem 1986:18:953-956.
9. Halliwell B, Gutteridge JMC: Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 1990; 186:1— 85.
10. Britton RS. Tavill AS. Bacon BR: Mechanisms ofiron toxicity: in Brock JH. HallidayJW. Pip-pard MJ. Powell LW (eds): Iron Metabolism in Health and Disease. London. Saunders. 1994. pp 311-351.
11. Seymour CA, Peters TJ: Organelle pathology in primary and secondary haemochromatosis with special reference to lysosomal changes. Br J Haematol 1978;40:239-253.
12. Link G, Hershko C: Rat heart cells in culture: A model of iron toxicity and chelation. J Lab Clin Med 1993;122:14-16.
13. Iancu TC: Ultrastructural pathology of iron overload. Baillieres Clin Hematol 1989:2:375— 395.
14. Bassett ML, Halliday JW, Lawrie WP: Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatologv 1986: 6:24-29.
15. Walker RJ, Miller JPG, Dymolk JW, Stillkin KB. Williams R: Relationship of hepatic iron concentration to histochemical grading and to total chelatable body iron in conditions associated with iron overload. Gut 1977;132:1011 — 1014.
16. Gualdi R, Casalgrandi G, Montosi G, Ventura E, Pietrangelo A: Excess iron into hepatocytes is required for activation of collagen type 1 gene during experimental siderosis. Gastroenterology 1994:107:1118-1124.
17. Pietrangelo A. Gualdi R. Casalgrandi G, Geerts A, De Bleser P, Montosi G. Ventura E: Enhanced hepatic collagen type I mRNA expression into fat-storing cells in a rodent model of hemochromatosis. Hcpatology 1994:19: 714-721.
18. Hassidav JW, Cowlishaw JI., Russo AM, Powell LM: Serum ferritin in diagnosis of haemochromatosis. Lancet 1977;ii:621—624.
19. De Virgiliis S, Comacchia G, Sanna G, Argiolu F, Galanello R, Fiorelli G. Rais M, Cossu P, Bertolino F. Cao A: Chronic liver disease in transfusion-dependent thalassemia: Liver iron quantitation and distribution. Acta Haematol 1981;65:32-39.
20. Cazzola M. Borgna-Piagnatti C. De Stefano P. Bcrgamaschi G, Bongo IG, Dezza L. Avato F: Internal distribution of excess iron and sources ofsemm ferritin in patients with thalassaemia. Scand J Haematol 1983:30:289-296.
21. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrel DE, Harris JW: Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993:42:81 — 85.
22. Chapman RWG, Hussain MAM, Gorman A, Laulicht M, Politis D, Flynn DM, Sherlock S. Hoffhrand AV: Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalasemia. J Clin Pathol 1982:35: 481-486.
23. Fischer R, Heinrich HC: Biosusceptometry -Current status of clinical diagnostics and bio-magnetic research; in Hoke M (ed): Biomagnetism: Clinical Aspects. Amsterdam, Elsevier, 1992, pp 573-581.
24. Sciot R, van Eyken P, Facchetti F, Callca F, van der Steen K, van Kijck H, van Parys G, Desiret VJ: Hepatocellular transferrin receptor expression in secondary siderosis. Liver 1989; 9:52-61.
25. Houang MTW, Arozena X. Skalicka A, Huehns ER. Shaw DG: Correlation between computed tomographic values and liver iron content in thalassemia major with iron overload. Lancet 1979:i: 1322— 1323.
26. Olivieri NF, Grisaru D, Daneman A. Martin DJ, Rose V, Freedman MH: Computed tomography scanning of the liver to determine efficacy ofiron chelation therapy in thalassemia major. J Pediatr 1989; 114:427-430.
27. Guyadcr D. Gandon Y, Deungnier Y, Joua-nolle H, Loreal O. Simon M, Bourcl M. Carsin M, Brissol P: Evaluation of computed tomography in the assessment ofliver iron overload: A study of 46 cases of idiopathic hemochromatosis. Gastroenterology 1989;97:737-743.
28. Kaltwasser J P, Gottschalk R, Schalk KP. Hartl W: Non-invasivc quantification of liver iron-overload by magnetic resonance imaging. Br J Haematol 1990:74:360-363.
29. Chezmar JI, Nelson RC. Malko JA, Bernardino ME: Hepatic iron overload: Diagnosis and quantification by non-invasive imaging. Gas-trointest Radiol 1990:15:27-31.
30. Olivieri NF, Kucharzyck W, Liu P: Magnetic resonance imaging (MRI) of the iron loaded anterior pituitary gland in thalassemia major: Correlation of signal intensity, T2 relaxation and hormonal status. Blood 1990:76 (suppl 1): 278a.
31. Brittenham GM, Farrell DE. Harris DE. Feldman ES, Danish EH, Muir WA, Tripp JH, Bel-lon EM: Magnetic susceptibility measurement of human iron stores. N Engl J Med 1982:307: 1671-1675.
32. Rcbulla P, Modell B: Transfusion requirements and effects in patients with thalassemia major: Cooleycare Programme. Lancet 1991: 337:277-280.
33. Gabutti V: Current therapy for thalassemia in Italy. Ann NY Acad Sci 1990;612:268-274.
34. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melcvcndi C, Di Gregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassemia. Lancet 1989:i: 27-30.
35. Barosi G, Arbustini E, Gavazzi A, Grasso M. Pucci A: Myocardial iron grading by endomyocardial biopsy: A clinico-pathologic study on iron overloaded patients. Eur J Haematol 1989;42:382-388.
36. Wolfe L. Olivieri NF, Sallan D, Colan S, Rose V. Propper R. Freedman M, Nathan D: Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;312:1600-1603.
37. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW: Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991;118:540-545.
38. Gabutti V, Piga A. Sacchetti L, Sandri A. Bigi-nclli M, Saracco P, Ferri M: Quality of life and life expectancy in thalassemic patients with complications; in Buckner CD. Gale RP. Lucarelli G (eds): Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches. New York. Liss. 1989. pp 35-41.
39. Wonke B, HofTbrand AV, Aldouri MA, Ward SE: Cardiac complications ¡11 homozygous bcta-thalassemia; in Buckner CD, Gale RP. Lucarelli G (eds): Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches. New York. Liss. 1989. pp 51-56.
40. Ehlers KH, Levin AR, Markenson AL: Longitudinal study of cardiac function in thalassemia major. Ann NY Acad Sci 1980:344:397-404.
41. Merkel PA, Simonson DC, Amiel SA, Plewc G. Sherwin RS, Pearson HA. Tamgortane WV: Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988,318:809-814.
42. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F: Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988; 63:58-62.
43. Cavallo-Perin P. Pacini G, Cerotti F, Bessone A, Condo C. Sacchetti L, Piga A. Pagano G: Insulin resistance and hyperinsulinemia in homozygous p thalassemia. Metabolism 1995;44: 281-286.
44. De Sanctis V. Pintor C. Aliquò, MC: Prevalence of endocrine complications in patients with p-thalassemia major: An Italian multicenter study; in Pintor C. Muller EE. Loche S, New MI (eds): Advances in Pediatric Endocrinology. Berlin, Springer. 1992, pp 127-133.
45. Hoffbrand AV, Wonke B: Results of long-term subcutaneous desferrioxamine therapy. Bail-lieres Clin Hematol 1989:2:345-362.
46. Aldouri MA, Wonke B. HofTbrand AV, Flynn DM, Laulicht M, Fenton LA, Scheuer PJ, Kibbler CC. Allwood CA. Brown D, Thomas HC: Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J Clin Pathol 1987;40:1353-1359.
47. Comer GM, Ozick LA, Sachdcv RK. Kumar S, Taunk GL. Smith J A. Lee TP. Clain DJ: Transfusion-related chronic liver disease in sickle cell anemia. Am J Gastroenterol 1991:86:1232-1234.
48. Jean G. Terzoli S, Mauri R. Borghetti L, Di Palma A, Piga A, Magliano M, Mclcvcndi M, Cattaneo M: Cirrhosis associated with multiple transfusions in thalassaemia. Arch Dis Child 1984;59:67-70.
49. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
50. Gabutti V, Piga A, Sacchetti L, Prioro M, Scagni P: Long term results of standard management in thalassemia (abstract). 5th Int Conf Thalassaemias and the Haemoglobinopathies, Nicosia, 1993, p 90.
51. Borgna-Pignatti C. De Stefano P. Zonta L., Vul-lo C, De Santis V, Melevendi C, Naselli A, Masera G, Terzoli S, Piga A, Gabutti V: Growth and sexual maturation in thalassemia major: A survey of 250 adolescents. J Pediatr 1985:106:150-155.
52. Borgna-Piagnatti C, Zurlo MG, De Stefano P, Boffa C. De Sanctis V. Di Palma A, Di Gregorio L. Melevendi C, Piga A. Sabato V: Outcome of thalassemia treated with conventional therapy. Bone Marrow Transplant 1993:12(suppl I): 2-4.
53. Saenger P. Schwartz E. Markenson AL. Graziano JH, Levine LS. New MI, Hilgartner MW: Depressed serum somatomedin activity ¡11 beta-thalassemia. J Pediatr 1980:96:214-218.
54. De Sanctis V. Vullo C, Katz M. Wonke B, Hoffbrand V, Bagni B: Hypothalamic pituitary gonadal axis in thalassemic patients with secondary amenorrhea. Obstet Gynecol 1988:72: 643-647.
55. Keberle H: The biochemistry of dcsferrioxam-ine and its relation to iron metabolism. Ann NY Acad Sci 1964:119:758-768.
56. Pippard MJ, Johnson DK, Finch CA: Hepato-cyte iron kinetics in the rat explored with an iron chelator. Br J Haematol 1982:52:211 —224.
57. Pippard MJ: Desferrioxamine-induccd iron excretion in humans. Baillieres Clin Hematol 1989;2:323-343.
58. Hershko C: Determinants of fecal and urinary' iron excretion in desferrioxamine-treated rats. Blood 1978:51:415-423.
59. Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C: Studies in desferrioxamine and fer-rioxaminc metabolism in normal and iron-loaded subjects. Br J Haematol 1979:42:547— 555.
60. Propper RD, Shuring SB, Nathan DG: Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 1976:294:1421— 1423.
61. Modell CB. Beck J: Long-term desferrioxamine therapy in thalassemia. Ann NY Acad Sci 1974;232:201-210.
62. Fosburg MT. Nathan DG: Treatment of Cooley’s anemia. Blood 1990;76:435-444.
63. Barry M, Flynn DM, Letsky EA, Risdon RA: Long-term chelation in thalassaemia major: Effect on liver iron concentration, liver histology and clinical progress. BrMcdJ 1974:i: 16—21.
64. Modell B, Letsky EA. Flynn DM, Peto R, Wea-therall DJ: Survival and desferrioxamine in thalassaemia major. Br Med J 1982:284:1081-1084.
65. Cohen A, Martin M, Schwartz E: Response to long-term deferoxamine therapy in thalassemia. J Pediatr 1981:99:689-694.
66. Giardina PJ, Grady RW, Ehlers KH, Burstein S, Graziano JH, Markenson AL, Hilgartner MW: Current therapy of Cooley’s anemia: A decade of experience with subcutaneous desfcr-rioxamine. Ann NY Acad Sci 1990:612:275— 285.
67. Pearson HA. Rink L. Guiliotis DK: Thalassemia major in Connecticut: A 20-year study of changing age distribution and survival. Conn Med 1994;58:259-260.
68. Pippard MJ: Iron chelation therapy in the treatment of iron overload; in Bergeron RJ. Brittenham GM (eds): The Development of Iron Chelators for Clinical Use. Boca Raton. CRC. 1994. pp 57-74.
69. De Virgiliis S, Congia M. Frau F. Argiolu F. Diana G, Cucca F, Varsi A, Sanna G, Padda G. Fodde M. Pirastu GF. Cao A: Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988:113:661-669.
70. Piga A Luzzatto L. Capalbo P, Gambotto S. Tricta F, Gabutti V: High-dose desferrioxamine as a cause of growth failure in thalassemic patients. Eur J Haematol 1988:40:380—381
71. Cohen A, Martin M, Schwartz E: Depiction of excessive liver iron stores with desferrioxam-ine. Br J Haematol 1984;58:369-373.
72. Gabutti V, Luzzatto L, Sandri A, Capalbo P. D'Oria A. Sacchetti L, Tricta F. Piga A: Toxicity of desfernoxamine treatment; in Kattamis C (ed): Iron Overload and Chelation in Thalassaemia. Bern, Huber, 1987, pp 26-33.
73. Olivieri NF, Koren G. Harris J, Khattak S, Freedman MH. Templeton DM. Bailey JD. Reilly BJ: Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hema-tol Oncol 1992;14:48-56.
74. Olivieri NF, Buncic RJ, Chew E, Gallanti T, Harrison RV, Keenan N, Logan N, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH: Visual and auditory neurotoxicity in patients receiving sub-cutaneous deferoxamine infusions. N Engl J Med 1986;314:869-873.
75. Gallant T, Bovden MH, Gallant LA. Carley H, Freedman MH: Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am J Med 1987;83:1085-1090.
76. Albera R, Pia F, Morra B, Lacilla M. Bianco L, Gabutti V, Piga A: Hearing loss and desferriox-amine in homozygous beta-thalassemia. Audi-ology 1988;172:1-8.
77. Piga A, Mandrino M, Bianco L, Albera L, Di Palma A, Vullo C, Stura M, Melevendi C, Ari-gliani R, Terzoli S, Camelli V, Tomotti G, Monguzzi W, De Stefano P, Borgna-Pignatti C: Hearing loss and desferrioxamine (abstract). 2nd Int Conf on Thalassemia and Hemoglobinopathies. Heraklion, 1987. pill.
78. Davies MJ, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER: Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;ii;181—184.
79. Arden GB, Wonke B, Kennedy C, Huehns ER: Ocular changes in patients undergoing longterm desferrioxamine treatment. Br J Ophthalmol 1984;68:873-877.
80. Lakhanpal V, Schocket SS, Jiji R: Desferrioxamine induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984;91:443-451.
81. De Virgiliis S. Congia M, Turco MP. Frau F, Dessi C. Argiolu F, Sorcinelli R. Sitzia A. Cao A: Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child 1988;63: 250-255.
82. Koren G. Bentur Y. Strong D, Harvey E, Klein J, Baumal R, Spielberg SP, Freedman MH: Acute changes in renal function associated with deferoxamine therapv. Am J Dis Child 1989; 143:1077-1080.
83. Freedman MH, Grisaru D, Olivieri N, Mac-Lusky I, Thomer PS: Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child 1990;144:565-569.
84. Porter JB, Jaswon MB, Huehns ER, East CA, Hazell JW: Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989:73:403-409.
85. Robin-Browne RM. Prpic JK. Stuard SJ: Ycr-siniac and iron: A study in host-parasite relationships. Contrib Microbiol Immunol 1987;9: 254-258.
86. Gallant T, Freedman MH, Vellcnd H, Fran-combe WH: Yersinia sepsis in patients with iron overload treated with deferoxamine. N Engl J Med 1986;314:1643.
87. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE. Agnew JE, Hilson AJ: High incidence of cardiomyopathy in beta-thaias-saemia patients receiving regular transfusion and iron chelation: Reversal by intensified chelation. Acta Haematol 1990;84:113-117.
88. Freeman AP, Giles RW, Berdoukas VA: Early left ventricular dysfunction and chelation therapy in thalassaemia major. Ann Intern Med 1983;99:450-454.
89. Olivieri NF, Nathan DG, MacMillan JH. Wayne AS. Liu PP, McGee A, Martin M. Koren G. Cohen AR: Survival in medically treated patients with homozygous p-thalassemia. N Engl J Med 1994:331:574-578.
90. Bronspicgel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ: Effect of age at the start of iron chelation therapy on gonadal function in b-thalassemia major. N Engl J Med 1990;323:713-719.
91. Cao A, Gabutti V. Masera G. Modell B, Sirchia G: A short guide to the management of thalassemia; in Sirchia G, Zanella A (eds): Thalassaemia Today: The Mediterranean Experience. Milan, Centro Trasfusionale Ospedale Maggiore Policlinico, 1987, pp 635-670.
92. Piga A: Computhal: A computerized clinical record for thalassemia; in Rebulla P. Fessas PH (eds): Thalassemia 1990. Milan, Centro Trasfusionale Ospedale Maggiore Policlinico, 1991, pp 139-151.
93. Gabutti V, Borgna Pignatti C: Clinical manifestations and therapy of transfusional haemo-siderosis. Baillieres Clin Haematol 1994;7: 919-940.
94. Hoffbrand AV, Gorman A, Laulicht M, Garidi M, Economidou J, Georgipoulou P, Hussain MAM, Flynn DM: Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet 1979;i:947—949.
95. Grisaru D, Goldfarb AW, Gostman MS, Rach-milewitz EA, Hasin Y: Deferoxamine improves left ventricular function in beta-thalassemia. Arch Intern Med 1986;146:2344-2349.
96. Freeman AP. Giles RW. Berdoukas VA, Talley PA, Murray IP: Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clin Lab Haematol 1989; 11: 299-307.
97. Flynn DM, Hoffbrand AV, Politis D: Subcutaneous desferrioxamine: The effect of three years treatment on liver iron, serum ferritin anc comments for echocardiography. Birth Defects 1982:18:347-353.
98. Landau H, Matoth I, Landau Cordova Z, Goldfarb A, Rachmilewitz EA, Glaser B: Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clin Endocrinol 1993:38:55— 61.
99. Forni M, Morra I, Sandri A, Sacchetti L, Piga A, Gabutti V: Evaluation at autopsy of iron overload in different tissues in thalassemia major (abstract) Proc Int Symp Bone Marrow Transplantation and Related Problems. Urbino, Sep 1988.
100. Brittenham GM. Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
101. Massaglia P. Carpignano M: Psychology of thethalassemic patient and his family; in Sirchia G, Zanella A (eds): Thalassaemia Today: The Mediterranean Experience. Milan. Centro Trasfusionale Ospedale Maggiore Policlinico. 1987, pp 69-79.
102. Piga A, Magliano M, Bianco L, Capalbo P, Boccaccini R, Gabutti V: Compliance with chelation therapy in Torino: in Sirchia G, Zanella A (eds): Thalassaemia Today: The Mediterranean Experience. Milan. Centro Trasfusionale Ospedale Maggiore Policlinico, 1987, pp 141-145.
103. Tsiantis J: Family reactions and relationships in thalassemia. Ann NY Acad Sci 1990;612: 451-461.
104. WHO Working Group on the Psychosocial Aspects of Thalassemia: Recommendations for Psychological and Social Management anc Support. Athens, Tettamanti, 1990.
105. Piga A. Priore M. Sandri A, Mandrino M, Kreitmaier U: A new system for subcutaneous infusion of desferrioxamine. Ann NY Acad Sci 1990;612:577-578.
106. Cohen A. Mizanin J. Schwartz E: Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr 1989;115:151-155.
107. Olivieri NF, Berriman AM, Tyler BJ, Davis SA, Francombe WH, Liu PP: Reduction in tissue iron stores with a new regimen of continuous ambulatory' intravenous deferoxamine. Am J Hematol 1992;41:61-63.
108. Piga A. Lanza C, Sacchetti L, Lcrro P: Deferoxamine chelation by intravenous implantable systems (abstract). 3rd Symp on the Development of Iron Chelators for Clinical Use, Gainesville, 1992.